Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Clinical Trials in the Northwest

Summer 2001

Primary Infection Clinic
Treatment and observational studies of newly acquired HIV infection (within the prior 8 months). Treatment options are abacavir, lamivudine, efavirenz OR abacavir, lamivudine, indinavir/ritonavir. Contact either Claire or Janine @ 206-720-4340.

Detection of HIV in HSV Lesions
The study follows subjects through 2 genital herpes [HSV-2] recurrences to determine if valacyclovir reduces detectable HIV in herpes lesions. Participants must have recognized recurrent genital HSV-2 and not be on chronic suppressive HSV therapy. $125 per recurrence. Contact Steve @ 206-720-4340.

Gay Couples HHV-8 Study
Two-year study of the Kaposi's sarcoma herpes virus to characterize the role of oral transmission and to determine if a primary infection syndrome exists. Participants can be HIV-positive or HIV-negative and should be in a steady relationship. $100 per study participant with free testing/counseling. Contact Steve @ 206-720-4340.

ACTG 5030
Preventing cytomegalovirus (CMV) organ damage with valganciclovir. Main eligibility includes: having antibodies to CMV, a CD4 <100, and a viral load >400. Payment for some clinic visits. Contact Alyssa @ 206-731-3184.

Advertisement
ACTG 5068
Structured treatment interruption (STI) and a vaccine. Subjects will receive antiretroviral drugs with STI, and either the ALVAC-HIV vCP1452 (canary pox) vaccine or a vaccine placebo. Requires person on first anti-HIV combination (unless switched because of side effects), and no prior use of abacavir or recent use of hydroxyurea. Payment for participation in sub-studies (men only). Contact Alyssa @ 206-731-3184.

ACTG 5076
Resistance testing. Genotyping versus phenotyping for treatment planning. Main requirements are that subject is planning to switch from their 2nd, 3rd, or 4th anti-HIV combination, and has had no prior resistance testing. Free resistance testing, and $10 for each clinic visit. Contact Alyssa @ 206-731-3184.

ACTG 5078
Carotid artery thickness. Ultrasound tests measure artery thickness in HIV-negative and HIV-positive participants. $25 paid for each ultrasound test. Contact Alyssa @ 206-731-3184.

ACTG 5090
Treatment of HIV-associated dementia. Selegiline transdermal system (STS patch) vs. patch placebo. All patients receive STS patch during 2nd half of study. Main eligibility is documented HIV dementia and on anti-HIV drugs for at least 8 weeks. $20 - $100 paid for some tests. Contact Alyssa @ 206-731-3184.

ACTG 5095
Initial treatment with a PI-sparing regimen. Subjects are randomly assigned to various combinations with ABC, 3TC, ZDV, EFV, and/or placebos. No prior antiretroviral treatment. Payment for some sub-studies. Contact Alyssa @ 206-731-3184.

ACTU 132
Effect of anti-HIV drugs on brain function and HIV in spinal fluid. Study involves one or more lumbar punctures (spinal taps), and subjects will be paid $100 - $150 for each. Contact Margot @ 206-731-3184.

HIV and Garlic Trial
Clinical study on the potential of garlic to lower high blood cholesterol. Must be on successful HAART for at least 6 months, with cholesterol >200, triglycerides <500. Compensation: $200 upon study completion. Contact Anne @ 206-834-4146.

Triangle FTC-301
Anti-HIV therapy for people who have never taken HIV drugs. Emtricitabine or stavudine, with ddI and Sustiva. Must have viral load of 5,000 or higher. Lab tests and study-related physical exams are free. Contact Janice @ 206-386-2523.

GlaxoSmithKline/CNA30024
Anti-HIV therapy for people who have never taken HIV drugs. Abacavir or AZT combined with 3TC and Sustiva. Must have viral load of 400 copies or higher, more than 50 T-helper cells. Lab tests and study-related physical exams are free. Contact Janice @ 206-386-2523.

GlaxoSmithKline CNA30021
Anti-HIV therapy for people who have never taken HIV drugs. Abacavir once a day or abacavir twice a day, with 3TC and Sustiva. CD4 count of 50 or more, viral load of 400 copies or higher. Lab tests and study-related physical exams are free. Contact Janice @ 206-386-2523.

GlaxoSmithKline ESS40013
Trizivir + Sustiva, randomized after 1 year to either same regimen or Trizivir alone. Never taken Sustiva, Viramune, or delavirdine. Less than two weeks of other anti-HIV drugs. Can substitute Viramune if Sustiva not tolerated. Lab tests and study-related physical exams are free. Contact Janice @ 206-386-2523.

Merck/CRX497
Anti-HIV therapy for patients with a failed regimen containing Sustiva, Viramune or delavirdine. Crixivan 800mg + Norvir 100mg twice a day or Viracept 1,250mg twice a day. Two other HIV drugs of the patient's/provider's choice will also be prescribed. Viral load of 2,000 copies or higher, more than 50 T-helper cells, never taken a protease inhibitor. Genotyping and phenotying will be performed. Contact Janice @ 206-386-2523.

Gilead Sciences/Tenofovir
Expanded access program. To provide tenofovir for persons needing a new antiviral in their treatment regimen. Contact Janice @ 206-386-2523.

HPTU 032 Gel Study
Study testing the safety of two different microbicidal gels compared to an over-the-counter lube people use during sex. Participants will be HIV-positive men. $25 at each visit. Contact Jeffery or Paul @ 206-521-5821.

HPTU -- Vision Study
HIV-negative men who have sex with men, including partners of HIV-positive men, needed for an 18-month study. $25 at each visit. Contact Jeffery or Paul @ 206-521-5821.

HVTU -- Multiple Exposures Study
Eligible participants are HIV-negative men or women repeatedly exposed to HIV by an HIV-positive partner. We are looking for BOTH partners. Participants are compensated for their time. Contact Jeffery or Paul @ 206-667-2300





  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Perspective.
 

Tools
 

Advertisement